Experimental cancer treatments for advanced stages are more effective than previously thought. Some oncology practitioners believe that experimental drugs are harmful - they give false hope to patients because of its low efficiency (long anticipated effectiveness of the experimental treatment with special drugs produced in Canadian pharmacy only at the level of 4-6% of cases). Patients in the final stage of the disease should have greater access to information about the experimental treatment programs, and, accordingly, they and their families should have the right to know what their real chances, with a particular treatment strategy. Scientists believe that the involvement of cancer patients even in the early stages of clinical trials can be very useful for them. Besides, the search for a way out of the situation means continuing the fight against the disease. It is characterized by academic phrase "treatment of metastatic cancer still remains palliative, with a very low probability of complete remission and cure the disease."

Work package 7


Establishment of a scaffold for the efficient dissemination of the results of IMMOMEC to the general public, scientific community and patients organizations, thereby promoting awareness of the obtained results.


For successful exploitation and dissemination of the project, the work has been organized in 4 distinct assignments. Partner 1 will be in charge of all tasks related to the dissemination process. All partners will participate in public meetings, secure input to the program, and communicate results in appropriate meetings and publications. Partners 2 and 3 will work towards commercialization. All partners will contribute to the awareness rising of the project on national as well as on international levels in the networks and associations they belong to. Any dissemination activities and publications in the project will acknowledge the EuropeanCommunity’s Seventh Framework Programme funding. In this regard, any scientific publication will state that the research leading to these results has received funding from the European Community’s Seventh FrameworkProgramme under the specific grant agreement for IMMOMEC.

Website: As an initial approach of knowledge dissemination, the consortium will establish a web site dedicated to IMMOMEC. This site will provide the basis for all internal and external communication concerning the project. For example, it will state the objectives, the work plan and the involved partners. Classified information will be on a restricted section of the site and be accessible to the participants. For external dissemination, information exchange and problem solving, a discussion platform will be implemented. The web site will also include aspecific subsection aimed at information for the general public as well as MCC patients. Partner 1 will be incharge of the design and maintenance of the website but every partner will contribute to the content of the site. The website will also acknowledge European Commision’s FP7 support and display the EU flag and FP7 logo. Public workshops and symposia meetings: Accompanying to the annual meetings, the consortium will arrangepublic workshops and/or symposia meetings to which the scientific community, patient organizations, policymakers and ethical committees will be invited. At these gatherings, advances, scientific progress and data fromthe clinical trial will be presented and discussed.

Communication to the scientific community: Communication to the scientific community will not be restricted to the website and the regular workshops/symposia but will also be done by presentation of the results at international meetings such as ESMO as well as via publication in open access peer-reviewed medical journals, and by submission to the European Clinical Trials Database (EudraCT).

Communication to the public: Communication of the clinical and scientific advances to the public and media will be a strong priority of the Consortium. This task will take place throughout the project. Networking with media is crucial to be able to communicate progress in the project to the outside world.

Exploitation of selected successful technologies: The protection and exploitation of research results anticipated as a direct result of the project and any unexpected spin-offs are of highest priority to the consortium and coordinator will continuously seek to raise awareness of IPR issues, ensuring that each participant in the projectis fully aware of the crucial need for attention on IPR matters for the success of the project. Manuscripts will be closely reviewed with particular attention paid to prospective patents. Consequently, both SME partners are directly involved in this WP. The detailed management of the IP likely to arise from the project will be ascertained in the Consortium Agreement.